The Long Duration Consequence of Using Anti-inflammatory and Immunosuppressive Drugs in the COVID-19 Epidemic-Scilight

Trends in Immunotherapy

Review

The Long Duration Consequence of Using Anti-inflammatory and Immunosuppressive Drugs in the COVID-19 Epidemic

Downloads

https://doi.org/10.54963/ti.v9i3.1036
Ismailov Imetkul, Mortada Saleh Hatem, Sura Akram Mohammed, Rafah Sabah Barrak, Ahmad Sabah, & Fakher Rahim. (2025). The Long Duration Consequence of Using Anti-inflammatory and Immunosuppressive Drugs in the COVID-19 Epidemic. Trends in Immunotherapy, 9(3), 61–76. https://doi.org/10.54963/ti.v9i3.1036
Volume 9 Issue 3 (September 2025) (in progress)
Copyright (c) 2025 Ismailov Imetkul, Mortada Saleh Hatem, Sura Akram Mohammed, Rafah Sabah Barrak, Ahmad Sabah, Fakher Rahim
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Ismailov Imetkul

    Department of Pathology, Basic and Clinical Pharmacology, Osh state university, Osh 723500, Kyrgyzstan
  • Mortada Saleh Hatem

    Department of Medical Laboratory analysis, Al Mansour University College, Baghdad 10067, Iraq
  • Sura Akram Mohammed

    Department of Medical Laboratory analysis, Al‑Turath University, Baghdad 10013, Iraq
  • Rafah Sabah Barrak

    Department of Medical Laboratory analysis, Al‑Rafidain University College, Baghdad 10064, Iraq
  • Ahmad Sabah

    Department of Medical Laboratory analysis, Madenat Alelem University College, Baghdad 10006, Iraq
  • Fakher Rahim

    Department of internal medicine, Osh state University, Osh 723500, Kyrgyzstan

Received: 17 February 2025; Revised: 4 March 2025; Accepted: 5 March 2025; Published: 23 July 2025

The SARS-2 virus, responsible for the COVID-19 epidemic in early 2020, persists in posing a hazard to public health through the emergence of new mutations and surges in prevalence across several nations. Immunosuppressive medications treat both short-term and long-term inflammatory illnesses. The classification of these medications into various types is based on their action mechanisms. It is important to review the most recent data on the effectiveness and side effects of administering these drugs to patients because of the risk of severe inflammatory repercussions in COVID-19 patients, including acute respiratory failure and cytokine storm. This article presents accurate data on the advantages and disadvantages of using immunosuppressive medications in COVID-19 patients, while also providing a concise overview of the various types of these medications. Taken together, anti-inflammatory drugs and immune response inhibitors seem to be associated with better outcomes, such as shorter hospital stays and less need for mechanical ventilation, faster recovery from acute symptoms, and lower mortality rates, especially in the critically ill. However, one must consider the possibility of increasing treatment duration and vulnerability to fungal and bacterial infections. To minimize the negative effects of these medications, it is important to carefully balance their dosage and administration timing. Overall, the utilization of immunosuppressive medications, whether administered recently during illness or consistently for non-COVID-19 reasons, appears to have a beneficial impact on managing inflammation, expediting recovery, and decreasing mortality. However, it is crucial to exercise caution and avoid prescribing these drugs without proper consideration.

Keywords:

Coronavirus; COVID‑19; Immune System; Corticosteroid; Immunosuppression

References

  1. Ramesh, S.; Govindarajulu, M.; Parise, R.S.; et al. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines (Basel) 2021, 9, 1195.
  2. Ghanbari, R.; Teimoori, A.; Sadeghi, A.; et al. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiol 2020, 15, 1747–1758.
  3. Cao, Y.; Li, L.; Feng, Z.; et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov 2020, 6, 11.
  4. Harmooshi, N.N.; Shirbandi, K.; Rahim, F. Environmental concern regarding the effect of humidity and temperature on 2019-nCoV survival: fact or fiction. Environ Sci Pollut Res Int 2020, 27, 36027–36036.
  5. Khafaie, M.A.; Rahim, F.; Cross-Country Comparison of Case Fatality Rates of COVID-19/SARS-COV-2. Osong Public Health Res Perspect 2020, 11, 74–80.
  6. Ghasemi, S.; Harmooshi, N.N.; Rahim, F. Diagnostic utility of antigen detection rapid diagnostic tests for Covid-19: A systematic review and meta-analysis. Diagn Pathol 2022, 17, 36.
  7. Ansari, N.; Jahangiri, M.; Shirbandi, K.; et al. The association between different predictive biomarkers and mortality of COVID-19. Bull Natl Res Cent 2022, 46, 158.
  8. Verma, G.; Dhawan, M.; Saied, A.A.; et al. Immunomodulatory approaches in managing lung inflammation in COVID-19: A double-edge sword. Immun Inflamm Dis 2023, 11, e1020.
  9. Hotchkiss, R.S.; Monneret, G.; Payen, D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13, 260–268.
  10. Khorasani Esmaili P.; Dabiri, S.; Reza Mirshekari, T.; et al. Rhinocerebral Mucormycosis Following COVID-19 Infection in Iran. Iran J Pathol 2023, 18, 116–124.
  11. Monreal, E.; Sainz de la Maza, S.; Fernández-Velasco, J.I.; et al. The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19. J Clin Immunol 2021, 41, 315–323.
  12. Yang, L.; Liu, S.; Liu, J.; et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Tar 2020, 5, 128.
  13. Williams, P.C.M.; Howard-Jones, A.R.; Hsu, P.; et al. SARS-CoV-2 in children: Spectrum of disease, transmission and immunopathological underpinnings. Pathology 2020, 52, 801–808.
  14. Dhochak, N.; Singhal, T.; Kabra, S.K.; et al. Pathophysiology of COVID-19: Why Children Fare Better than Adults? Indian J Pediatr 2020, 87, 537–546.
  15. Galindo, R.; Chow, H.; Rongkavilit, C. COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am 2021, 68, 961–976.
  16. Tomasi, L.; Thiriard, A.; Heyndrickx, L.; et al. Younger Children Develop Higher Effector Antibody Responses to SARS-CoV-2 Infection. Open Forum Infect Dis 2022, 9, ofac554.
  17. Vono M.; Huttner A.; Lemeille S.; et al. Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. Cell Rep 2021, 37, 109773.
  18. Phan, H.V.; Tsitsiklis, A.; Maguire, C.P.; et al. Host-microbe multiomic profiling reveals age-dependent immune dysregulation associated with COVID-19 immunopathology. Sci Transl Med 2024, 16, eadj5154.
  19. da Silva, R.P.; Thomé B.L.; da Souza, A.P.D. Exploring the Immune Response against RSV and SARS-CoV-2 Infection in Children. Biology (Basel) 2023, 12, 1223.
  20. Peeples, L. Understanding Kids and COVID. Proc Natl Acad Sci USA 2022, 119, e2203753119.
  21. Dioguardi, M.; Cazzolla, A.P.; Arena C.; et al. Innate Immunity in Children and the Role of ACE2 Expression in SARS-CoV-2 Infection. Pediatr Rep 2021, 13, 363–382.
  22. Tobinick, E. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr Med Res Opin 2004, 20, 39–40.
  23. Atanasova, K.; Van Gucht, S.; Van Reeth, K. Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs. Vet Immunol Immunopathol 2010, 137, 12–19.
  24. Fu, Y.; Cheng, Y.; Wu, Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin 2020, 35, 266–271.
  25. Fang, L.; Karakiulakis, G.; Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020, 8, e21.
  26. Richardson, P.; Griffin, I.; Tucker, C.; et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020, 395, e30–e31.
  27. Ma, Y.; Wang, C.; Xue, M.; et al. The Coronavirus Transmissible Gastroenteritis Virus Evades the Type I Interferon Response through IRE1α-Mediated Manipulation of the MicroRNA miR-30a-5p/SOCS1/3 Axis. J Virol 2018, 92(22): e00728-18.
  28. Yang, C.W.; Lee, Y.Z.; Hsu, H.Y.; et al. Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity. Sci Rep 2017, 7, 4105.
  29. Wathelet, M.G.; Orr M.; Frieman, M.B.; et al. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol 2007, 81, 11620–11633.
  30. Chen, L.; Liu, H.G.; Liu, W.; et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020, 43, E005.
  31. Guimarães, P.O.; Damiani, L.P.; Tavares, C.A.M.; et al. Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial. Einstein (Sao Paulo, Brazil) 2024, 22, eAO0821.
  32. Franchimont, D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 2004, 1024, 124–137.
  33. Röpke, C.; Gladstone, P.; Nielsen. M.; et al. Apoptosis following interleukin-2 withdrawal from T cells: evidence for a regulatory role of CD18 (beta 2-integrin) molecules. Tissue Antigens 1996, 48, 127–135.
  34. Lee, D.S.W.; Rojas, O.L.; Gommerman, J.L. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 2021, 20, 179–199.
  35. Dehelean, C.A.; Lazureanu, V.; Coricovac, D.; et al. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. J Clin Med 2020, 9.
  36. Horby, P.; Lim, W.S.; Emberson, J.R.; et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021, 384, 693–704.
  37. Alipanah-Lechner, N.; Hurst-Hopf, J.; Delucchi, K.; et al. Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial. Crit Care 2024, 28, 56.
  38. Bhutani, M.; Foureau, D.M.; Robinson, M.; et al. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse. Clin Lymphoma Myeloma Leuk 2023, 23, 535–544.e1.
  39. Cárdenas, G.; Chávez-Canales, M.; Espinosa, A.M.; et al. Intranasal Versus Intravenous Dexamethasone to Treat Hospitalized COVID-19 Patients: A Randomized Multicenter Clinical Trial. Arch Med Res 2024, 55, 102960.
  40. Salton, F.; Confalonieri, P.; Centanni, S.; et al. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). Eur Respir J 2023, 61.
  41. Taher, A.; Lashkari, M.; Keramat, F.; et al. Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: aprospective three-arm randomized clinical trial. Wien Med Wochenschr 2023, 173, 140–151.
  42. Wadhwa, B.; Malhotra, V.; Kerai, S.; et al. Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi. BMC Infect Dis 2023, 23, 326.
  43. Bahsoun, A.; Fakih, Y.; Zareef, R.; et al. Corticosteroids in COVID-19: pros and cons. Front Med (Lausanne) 2023, 10, 1202504.
  44. Mishra, G.P.; Mulani, J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir Med 2021, 9(1), e8.
  45. Ssentongo, P.; Yu, N.; Voleti, N.; et al. Optimal Duration of Systemic Corticosteroids in Coronavirus Disease 2019 Treatment: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases 2023, 10.
  46. de Ligt, M.; Hesselink, M.K.C.; Jorgensen, J.; et al. The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19. Obesity (Silver Spring, Md) 2021, 29, 1423–1426.
  47. Nouri-Vaskeh M.; Kalami N.; Zand R.; et al. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial. Int J Clin Pract 2021, 75, e14124.
  48. Mancia, G.; Rea, F.; Ludergnani, M.; et al. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020, 382, 2431–2440.
  49. Gnanenthiran, S.R.; Borghi, C.; Burger, D.; et al. Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension. J Am Heart Assoc 2022, 11, e026143.
  50. Zhang, X.; Yu, J.; Pan, L.Y.; et al. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Pharmacol Res 2020, 158, 104927.
  51. Wu, J.; Deng, W.; Li, S.; et al. Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci 2021, 78, 531–544.
  52. Jiang, H.; Chess, L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004, 114, 1198–1208.
  53. de Wilde, A.H.; Zevenhoven-Dobbe, J.C.; van der Meer, Y.; et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 2011, 92, 2542–2548.
  54. Kindrachuk, J.; Ork, B.; Hart, B.J.; et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Ch 2015, 59, 1088–1099.
  55. Assadiasl, S.; Fatahi, Y.; Zavvar, M.; et al. COVID-19: Significance of antibodies. Hum Antibodies 2020, 28, 287–297.
  56. Levavi, H.; Lancman, G.; Gabrilove, J. Impact of rituximab on COVID-19 outcomes. Ann Hematol 2021, 100, 2805–2812.
  57. Reddy, V.; Cohen, S. JAK Inhibitors: What Is New? Curr Rheumatol Rep 2020, 22, 50.
  58. Mosharmovahed, B.; Fatahi, Y.; Mohebbi, B.; et al. Tocilizumab in transplantation. Eur J Clin Pharmacol 2020, 76, 765–773.
  59. Siami, Z.; Hedayat Yaghoobi, M.; Karimi, P. Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study. Med J Islam Repub Iran 2023, 37, 92.
  60. Rubio-Rivas, M.; Forero, C.G.; Mora-Luján, J.M.; et al. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. Pharmacotherapy 2021, 41, 884–906.
  61. Lan, S.H.; Lai, C.C.; Huang, H.T.; et al. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents 2020, 56, 106103.
  62. Palau, V.; Riera, M.; Soler, M.J. ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol Dial Transplant 2020, 35, 1071–1072.
  63. Robinson, P.C.; Liew, D.F.L.; Liew, J.W.; et al. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med 2020, 1, 90–102.
  64. Çakmak, R.; Yüce, S.; Ay, M.; et al. Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study. Sci Rep 2024, 14, 12369.
  65. Huet, T.; Beaussier, H.; Voisin, O.; et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020, 2, e393–e400.
  66. Assadiasl, S.; Fatahi, Y.; Mosharmovahed, B.; et al. From Rheumatoid Arthritis to COVID-19. J Clin Pharmacol 2021, 61, 1274–1285.
  67. Qian, Y.; Raymundo, E.M.; Hao, S.; et al. Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis. Clin Ther 2024, 46, 733–741.
  68. Cao, Y.; Wei, J.; Zou, L.; et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): Amulticenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020, 146, 137–146.e133.
  69. Java, A.; Apicelli, A.J.; Liszewski, M.K.; et al. The complement system in COVID-19: friend and foe? JCI Insight 2020, 5.
  70. Fodil, S.; Annane, D. Complement Inhibition and COVID-19: The Story so Far. Immunotargets Ther 2021, 10, 273–284.
  71. Scott, L.J. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 2011, 25, 673–698.
  72. Barzegar, M.; Mirmosayyeb O.; Nehzat N.; et al. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm 2020, 7, e753.
  73. Dong, Y.; Shamsuddin, A.; Campbell, H.; et al. Current COVID-19 treatments: Rapid review of the literature. J Glob Health 2021, 11, 10003.
  74. Sayyah, M.; Shirbandi, K.; Rahim, F.; et al. Statin for Migraine Headache: Is It Worthwhile? Neurol India 2020, 68, 1003–1007.
  75. Esserman, L.J.; Berry, D.A.; DeMichele, A.; et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012, 30, 3242–3249.
  76. Wang, H.; Yee, D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Curr Breast Cancer R 2019, 11, 303–310.
  77. Files, D.C.; Aggarwal, N.; Albertson, T.; et al. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. Eclinicalmedicine 2023, 58.
  78. Calfee, C.S.; Liu, K.D.; Asare, A.L.; et al. Clinical trial design during and beyond the pandemic: the I-SPY COVID trial. Nat Med 2022, 28, 9–11.
  79. Blair, H.A. Remdesivir: A Review in COVID-19. Drugs 2023, 83, 1215–1237.
  80. Chen, C.; Zhang, Y.; Huang, J.; et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol 2021, 12, 683296.
  81. Amani, B.; Amani, B.; Zareei, S.; et al. Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis. Immun Inflamm Dis 2021, 9, 1197–1208.
  82. Cvetkovic, R.S.; Goa, K.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003, 63, 769–802.
  83. Bignardi, P.R.; Vengrus, C.S.; Aquino, B.M.; et al. Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. Pathog Glob Health 2021, 115, 139–150.
  84. Ali, H.S.; Elshafei, M.S.; Saad, M.O.; et al. Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study. Bmc Pulm Med 2021, 21, 354.
  85. Hashimoto, S.; Yoshizaki, K.; Uno, K.; et al. Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. Front Med (Lausanne) 2021, 8, 734838.
  86. Khan, Z.; Karataş, Y.; Rahman, H. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. Adv Ther 2020, 37, 2575–2579.
  87. Ahmed, S.; Khan, S.; Imran, I.; et al. Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. Vaccines (Basel) 2021, 9, 836.
  88. Mishra, N.T.P.; Das, S.S.; Yadav, S.; et al. Global impacts of pre- and post-COVID-19 pandemic: Focus on socio-economic consequences. Sens Int 2020, 1, 100042.
  89. Peters, G.J.; van der Wilt, C.L.; van Moorsel, C.J.A.; et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Therapeut 2000, 87, 227–253.
  90. Schälter, F.; Dürholz, K.; Bucci, L.; et al. Does methotrexate influence COVID-19 infection? Case series and mechanistic data. Arthritis Res Ther 2021, 23, 166.
  91. Balestri, R.; Rech, G.; Girardelli, C.R. Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus. J Eur Acad Dermatol Venereol 2020, 34, e435–e436.
  92. Chen, X.; Chou, C.Y.; Chang, G.G. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. Antivir Chem Chemother 2009, 19, 151–156.
  93. Swaim, C.D.; Dwivedi, V.; Perng, Y.C.; et al. 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro. Iscience 2021, 24, 103213.
  94. Balloux, F.; van Dorp, L. Q&A: What are pathogens, and what have they done to and for us? BMC Biol 2017, 15, 91.
  95. Uddin, N.; Acter, T.; Rashid, M.H.; et al. Coping with the COVID-19 pandemic by strengthening immunity as a nonpharmaceutical intervention: A major public health challenge. Health Sci Rep-Us 2023, 6, e1562.
  96. Lunjani, N.; Ahearn-Ford, S.; Dube, F.S.; et al. Mechanisms of microbe-immune system dialogue within the skin. Genes Immun 2021, 22, 276–288.
  97. Zhou, X.; Wu, Y.; Zhu, Z.; et al. Mucosal immune response in biology, disease prevention and treatment. Signal Transduct Tar 2025, 10, 7.
  98. Xiao, X.; Miao, Q.; Chang, C.; et al. Common variable immunodeficiency and autoimmunity – an inconvenient truth. Autoimmun Rev 2014, 13, 858–864.
  99. Nasir, N.; Mak A. Autoimmune Diseases. In International Encyclopedia of Public Health, 3rd ed; Quah, S.R. Ed.; Academic Press: Oxford, UK, 2025; pp. 428–435.
  100. Li, H.; Li, L.; Wang, X.; et al. HIV/AIDS. In Radiology of Infectious Diseases; Li, H. Eds.; Springer: Dordrecht, Netherlands, 2015; pp. 191–413.
  101. Rahim, F.; Khakimova, A.; Ebrahimi, A.; et al. Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis. Cell J 2021, 23, 523–531.
  102. Iddir, M.; Brito, A.; Dingeo, G.; et al. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. Nutrients 2020, 12.
  103. Alagawany, M.; Attia, Y.A.; Farag, M.R.; et al. The Strategy of Boosting the Immune System Under the COVID-19 Pandemic. Front Vet Sci 2020, 7, 570748.